As Arid1a deficiency seems to result in higher susceptibility to sorafenib treatment, screening for this mutation may enable the specific selection of HCC patients who are more likely to benefit from this systemic therapy [31]. The gene discussed is ARID1A; the disease is hepatocellular carcinoma.